Gas-X Recall has triggered a nationwide safety warning after regulators confirmed that several batches of the popular anti-gas medication may contain chemical contamination. Meanwhile, health officials and the manufacturer have urged consumers to stop using affected products immediately while investigations and product returns continue.
The recall involves Gas-X Extra Strength Softgels distributed across pharmacies and retail outlets nationwide. Additionally, authorities identified multiple production lots that may contain exposure to a coolant substance during packaging operations. The issue began after a manufacturing machine leaked during production, which created a contamination risk.
Furthermore, the manufacturer issued a voluntary recall after internal checks revealed possible exposure to a diluted propylene glycol-based coolant. Consequently, officials classified the situation as a precautionary safety measure even though no confirmed injuries exist. The affected products include specific bottle sizes commonly sold in 72-count and 120-count packaging formats.
In addition, regulators traced exact lot numbers linked to the Gas-X Recall, allowing retailers and consumers to identify impacted bottles more easily. These batches include several production codes with matching expiration dates set for late 2028. Therefore, distributors across the country removed stock from shelves and online listings.
Meanwhile, health experts explained that contaminated softgels could cause symptoms such as nausea, abdominal discomfort, vomiting, and diarrhea. However, officials emphasized that they have not documented any adverse reactions so far. Still, they advised consumers to take immediate precautionary steps and avoid using the affected medication.
Moreover, the company responsible for manufacturing said it identified and fixed the mechanical issue responsible for the leak. In addition, it confirmed that it implemented corrective measures to prevent similar incidents in future production cycles. Consequently, production lines resumed under revised safety protocols.
Retailers and distributors also received instructions to return or quarantine affected inventory. Furthermore, customers who purchased matching lot numbers can request refunds or replacement options through official return channels. Therefore, companies involved in distribution have started contact procedures with pharmacies and retail partners.
Ultimately, the Gas-X Recall highlights the importance of strict manufacturing oversight in over-the-counter medication production. As investigations continue, regulators and the manufacturer maintain ongoing monitoring of quality control systems to ensure consumer safety remains protected moving forward.
